Evidence map›Paper›PMID 28247181›Full record

ArticleMolecular diagnosis & therapy2017

Detection of PIK3CA Mutations in Plasma DNA of Colorectal Cancer Patients by an Ultra-Sensitive PNA-Mediated PCR.

Qian Zeng, Li Xie, Na Zhou, Min Liu, Xianrang Song

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diagnosis & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Qian ZengClinical Laboratory, Shandong Cancer Hospital & Institute, 440 Ji-Yan Road, Jinan, 250117, Shandong Province, People's Republic of China.
Li XieClinical Laboratory, Shandong Cancer Hospital & Institute, 440 Ji-Yan Road, Jinan, 250117, Shandong Province, People's Republic of China.
Na ZhouClinical Laboratory, Shandong Cancer Hospital & Institute, 440 Ji-Yan Road, Jinan, 250117, Shandong Province, People's Republic of China.
Min LiuClinical Laboratory, Shandong Cancer Hospital & Institute, 440 Ji-Yan Road, Jinan, 250117, Shandong Province, People's Republic of China.
Xianrang SongClinical Laboratory, Shandong Cancer Hospital & Institute, 440 Ji-Yan Road, Jinan, 250117, Shandong Province, People's Republic of China. sxr@vip.163.com.
Qilu Hospital of Shandong University · CNShandong First Medical University · CNShandong Tumor Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMutant Phosphatidylinositol-4, 5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) has been shown to be associated with the occurrence, development and prognosis in colorectal cancer (CRC). However, its detection has been limited because of complicated procedures and the low sensitivity of the present approaches.

methodsWe established an ultra-sensitive peptide nucleic acid-mediated polymerase chain reaction (PNA-PCR) assay to detect PIK3CA gene mutation in exon 9 and exon 20 with cell-free DNA (cfDNA). Using this technology, we detected the mutation status of PIK3CA in 128 colorectal cancer patients. 6 CRC patients receiving targeted therapy were chosen at random to undergo continuous PIK3CA mutation detection.

resultsThe results showed that the sensitivity of PNA-PCR clamping method was 0.1% for the exon 9 and 0.2% for the exon 20 variant alleles. When the PIK3CA mutation status was determined by PNA-PCR plus sequencing, 38.3% (49/128) of CRC carried at least one mutation, either E545Kor H1047R. The clinic-pathological parameters of age (p = 0.358), gender (p = 0.622), disease stage (p = 0.353) and disease location (p = 0.307) were not associated with the PIK3CA mutation. In the continuous monitoring study, we found that the gene status was associated with the effect of treatment. Furthermore, when the PIK3CA variant was determined by only the PNA-PCR method, there was a good linear relationship between ΔCp values and the proportion of variant DNA. The accuracy of PNA-PCR was 93.75 and 92.27% respectively when the cut-off values of ΔCp at 9.0 and 8.0 were set for determining the E545K and H1047R mutations.

conclusionsA simple, noninvasive, ultra-sensitive PNA-PCR technology was developed and was especially suitable for the dynamic detection of PIK3CA variants using cfDNA.

Indexed as

MutationAdultAgedClass I Phosphatidylinositol 3-KinasesColorectal NeoplasmsExonsFemaleGene ExpressionHumansMaleMiddle AgedPeptide Nucleic AcidsPolymerase Chain ReactionPrognosisSensitivity and SpecificityClass I Phosphatidylinositol 3-KinasesPeptide Nucleic AcidsPIK3CA protein, human

Identifiers

PMID28247181
OpenAlexW2591905761

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.